Publikationer 2013

Peer reviewed.

  1. Circulating CD36 is reduced in HNF1A-MODY carriers. Bacon S, Kyithar MP, Schmid J, Costa Pozza A, Handberg A, Byrne MM. P L o S One. 2013 sep 12;8(9):e74577.  
  2. CSF biomarker variability in the Alzheimer's Association quality control program. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S et al. Alzheimer's & Dementia. 2013 maj;9(3):251-61.
  3. High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. Petta S, Handberg A, Marchesini G, Cammà C, Di Marco V, Cabibi D et al. Journal of Viral Hepatitis. 2013 mar;20(3):174-82.
  4. Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. Petta S, Handberg A, Craxì A. Current Pharmaceutical Design. 2013;19(29):5193-218.
  5. The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial. Venø SK, Nielsen MR, Lundbye-Christensen S, Schmidt EB, Handberg A. Marine Drugs. 2013;11(9):3324-34.
  6. Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease. Wilhelmsen P, Kjær J, Thomsen KL, Nielsen CT, Dige AK, Maniecki MB et al. Archives of Physiology and Biochemistry. 2013 jul 17;119(5):202-8.
  7. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Faurholt-Jepsen D, Range N, PrayGod G, Jeremiah K, Faurholt-Jepsen M, Aabye MG et al. Tropical Medicine & International Health. 2013 jul;18(7):822-9.
  8. Vitamin D Status among Pulmonary TB Patients and Non-TB Controls: A Cross-Sectional Study from Mwanza, Tanzania. Friis H, Range N, Changalucha J, Praygod GA, Jeremiah K, Faurholt-Jepsen D et al. P L o S One. 2013;8(12):e81142.
  9. Adapted J6/JFH1-based hepatitis C virus recombinants with genotype-specific NS4A show similar efficacy to lead protease inhibitors, interferon-alpha and a putative NS4A inhibitor. Gottwein JM, Jensen SB, Serre SBN, Ghanem L, Scheel TKH, Jensen TB et al. Antimicrobial Agents and Chemotherapy. 2013;57(12):6034-6049.
  10. The prevalence of latent Mycobacterium tuberculosis infection based on an interferon-γ release assay: a cross-sectional survey among urban adults in Mwanza, Tanzania. Jensen AV, Jensen L, Faurholt-Jepsen D, Aabye MG, Praygod G, Kidola J et al. P L o S One. 2013;8(5):e64008.
  11. Socioeconomic status in HCV infected patients - risk and prognosis. Omland LH, Osler M, Jepsen P, Krarup H, Weis N, Christensen PB et al. Clinical Epidemiology. 2013;5:163-72.
  12. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome. Pedersen J, Jensen TB, Carlsen THR, Schønning K, Christensen PB, Laursen AL et al. P L o S One. 2013;8(5):e62674.
  13. Identification of IFN-alpha Induced Envelope Mutations of Hepatitis C Virus In Vitro Associated with Increased Viral Fitness and Interferon Resistance. Serre SBN, Krarup HB, Bukh J, Gottwein JM. Journal of Virology. 2013 sep 18;87(23):12776-93.
  14. Haptoglobin genotype and risk markers of cardiovascular disease in patients with chronic kidney disease. Strandhave C, Svensson MHS, Krarup H, Christensen JH. International Journal of Nephrology. 2013;2013:650847.
  15. Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish case-cohort study. El-Galaly TC, Severinsen MT, Overvad K, Steffensen R, Vistisen AK, Tjønneland A et al. British Journal of Haematology. 2013 mar;160(6):838-41.
  16. Alcohol intake and risk of venous thromboembolism. A Danish follow-up study. Gaborit FS, Overvad K, Nørgaard M, Kristensen SR, Tjønneland A, Severinsen MT. Thrombosis and Haemostasis. 2013 jul 1;110(1):39-45.
  17. Extracellular Vesicle (EV) Array: microarray capturing of exosomes and other extracellular vesicles for multiplexed phenotyping. Jørgensen M, Bæk R, Pedersen S, Søndergaard EKL, Kristensen SR, Varming K. Journal of extracellular vesicles. 2013;2.
  18. Impact of Incident Venous Thromboembolism on Risk of Arterial Thrombotic Diseases. Lind C, Flinterman L, Enga KF, Severinsen MT, Kristensen SR, Braekkan SK et al. Circulation (Baltimore). 2013 nov 22.
  19. Monitoring of anticoagulant therapy applying a dynamic statistical model. Nielsen PB, Lundbye-Christensen S, Larsen TB, Kristensen SR, Hejlesen O. Computer Methods and Programs in Biomedicine. 2013;110(3):380-388.
  20. Fish intake and venous thromboembolism: A Danish follow-up study. Severinsen MT, Overvad K, Andersen VL, Tjønneland A, Schmidt EB, Kristensen SR. Thrombosis Research. 2013 dec 31.
  21. Functional examination of MLH1, MSH2, and MSH6 intronic mutations identified in Danish colorectal cancer patients.Petersen SM, Dandanell M, Rasmussen LJ, Gerdes A-MA, Krogh LN, Bernstein I et al. B M C Medical Genetics. 2013;14:103.
  22. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. Couch FJ, Wang X, McGuffog L, Lee AR, Olswold C, Kuchenbaecker KB et al. P L o S Genetics. 2013 mar;9(3):1-21. e1003212.
  23. Influence of M-Component on the procoagulant state in Patients with Multiple Myeloma: does an increase in the M-component concentration, change the thrombogenic profile in plasma?.Pedersen S, Stausholm-Møller AK, Gregersen H, Münster A-MB. DSTH Forum. 2013;(3):17-21.
  24. GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. de la Morena-Barrio ME, Hernández-Caselles T, Corral J, García-López R, Martínez-Martínez I, Pérez-Dueñas B et al. Orphanet Journal of Rare Diseases. 2013;8:170.